# Prevention of Post-STEMI Left Ventricular Thrombus With Optimized Anticoagulant (EARLYmyo-LVT Ⅱ)

Study · id `cardio:ct-nct03786757` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03786757](<https://clinicaltrials.gov/study/NCT03786757>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03786757

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

## Technical summary

Registry record NCT03786757. Randomized; no masking; primary purpose prevention. Start 2019-04-01 (anticipated); primary completion 2022-03-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT03786757, source copy `cardio:ctgov-nct03786757-2018-12-26`, retrieved 2026-10-26)
- Planned start: 2019-04-01 (anticipated) (ClinicalTrials.gov record NCT03786757, source copy `cardio:ctgov-nct03786757-2018-12-26`, retrieved 2026-10-26)
- Primary completion: 2022-03-30 (anticipated) (ClinicalTrials.gov record NCT03786757, source copy `cardio:ctgov-nct03786757-2018-12-26`, retrieved 2026-10-26)
- Completion: 2022-12-30 (anticipated) (ClinicalTrials.gov record NCT03786757, source copy `cardio:ctgov-nct03786757-2018-12-26`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT03786757, source copy `cardio:ctgov-nct03786757-2018-12-26`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03786757-2018-12-26`, retrieved 2026-10-26)

## The registry's words

- Brief title: Prevention of Post-STEMI Left Ventricular Thrombus With Optimized Anticoagulant (EARLYmyo-LVT Ⅱ)
- Condition: ST Segment Elevation Myocardial Infarction
- Condition: Left Ventricular Thrombus
- Intervention (Drug): Rivaroxaban
- Lead sponsor: RenJi Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry intervention name matches this record: Rivaroxaban (`cardio:rivaroxaban`)
- Registry lists this organization as the lead sponsor: RenJi Hospital (`cardio:org-renji-hospital`)

## Provenance

Content hash: 5decfa0cdc48448f42af4a96875023a11ed835aae9453b0ddd6b3d0e7ba07521
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
